Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average of $4.62

Daré Bioscience, Inc. (NASDAQ:DARE) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.62 and traded as low as $3.42. Daré Bioscience shares last traded at $3.55, with a volume of 13,506 shares trading hands.

Wall Street Analysts Forecast Growth

DARE has been the subject of several recent analyst reports. Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th. HC Wainwright restated a “buy” rating and issued a $72.00 price target on shares of Daré Bioscience in a research note on Wednesday, May 15th. Finally, Brookline Capital Management upgraded Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Wednesday, May 15th.

Daré Bioscience Trading Up 3.8 %

The company has a market capitalization of $29.89 million, a price-to-earnings ratio of -0.92 and a beta of 1.37. The company has a fifty day moving average of $3.75 and a 200-day moving average of $4.63.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.